|
Jun 6
|
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
|
|
Jun 6
|
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
|
|
Jun 6
|
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
|
|
Jun 5
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jun 5
|
Global Markets Are On a Tear. These Stocks in Europe and Japan Are Still Bargains.
|
|
Jun 4
|
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
|
|
Jun 3
|
AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment
|
|
Jun 3
|
UK Stocks That Might Be Priced Below Estimated Value
|
|
Jun 2
|
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
|
|
Jun 2
|
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
|
|
Jun 2
|
ASCO25: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer
|
|
Jun 2
|
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
|
|
Jun 2
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
|
|
Jun 2
|
AstraZeneca Says DATROWAY Shows Promising Results in Combination Trials for Lung Cancer
|
|
May 23
|
European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially
|
|
May 23
|
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
|
|
May 21
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
May 21
|
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust
|
|
May 21
|
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
|
|
May 21
|
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
|